The postnatal rise in blood oxygen tension is widely recognised as the trigger to closure of the ductus arteriosus. The prostaglandins are increasingly recognised as the mediators of this phenomenon.1 One suggested mechanism is that increased oxygen tension may promote the conversion of arachidonic acid to prostaglandin F2a, which is known to be present in ductus arteriosus tissue and is a ductus constrictor. Another is that patency of the fetal ductus arteriosus may be actively sustained by intramural prostaglandin E2 (PGE2) and that postnatal exposure to oxygen reduces the responsiveness of the ductus to PGE2. There are certain clinical conditions in which the oxygen trigger does not seem to operate fully-for example, the ductus arteriosus often closes in congenital right heart obstructive lesions despite severe hypoxaemia, while it often remains patent in premature infants despite normal blood oxygen tensions. Treatment has been directed on the one hand towards the use of the E type prostaglandins to maintain ductus arteriosus patency and on the other towards the drug inhibition of prostaglandin synthesis to encourage ductus constriction. Indomethacin has been the drug most widely used as a prostaglandin synthetase inhibitor. The overall mortality did not differ significantly whether infants were given usual medical treatment with indomethacin initially or later or whether they proceeded to surgical ligation of the ductus arteriosus having been in the placebo or the indomethacin group. The surgical group, however, had a higher complication rate, especially pneumothorax and retrolental fibroplasia, and the infants who were given indomethacin as part of the initial treatment had a higher incidence of bleeding than those to whom it was given only when usual medical treatment had failed. Bronchopulmonary dysplasia and necrotising enterocolitis had a similar incidence in each of these groups. In a follow up evaluation at the age of 1 year there were no significant differences between the groups in terms of the proportion of infants with poor outcome.3
Management of patent ductus arteriosus in
Conclusions. There seems to be some merit in using intravenous indomethacin in those infants with a notable patent ductus arteriosus who do not respond to 36-48 hours of fluid restriction and diuretics and in whom there is no contraindication to its use.
Approximately one quarter of all infants with a haemodynamically significant patent ductus arteriosus would then probably require surgical closure compared with two thirds if indomethacin was not used. The multi-centre study did not report whether the results varied from one centre to another. The timing of surgical closure of the ductus would probably have been based on the individual clinical assessment of each infant and might conceivably have influenced the outcome in the various centres. Small randomised studies have been reported in which infants were given indomethacin as a prophylactic measure.4 Although a lower incidence of subsequent appreciable shunting was shown, there were more complications, and the overall benefits of this strategy must remain speculative. patency allowed the descending aorta and kidneys to be perfused from the pulmonary artery. The other application of treatment with prostaglandin E is the presence of complete transposition of the great arteries when interatrial mixing is poor, either before or after balloon atrial septostomy.7 The increased flow through the ductus arteriosus from the aorta to the pulmonary artery then results in an increase in pulmonary blood flow and an increased pulmonary venous return to the left atrium. The left atrial pressure rises, encouraging the flow of oxygenated blood across the interatrial communication into the right heart and the systemic circulation.
Clinical evaluation of treatment with prostaglandin. An extensive assessment of the use of infusion of PGE, in treating infants with ductus dependent congenital heart disease was undertaken in a collaborative clinical trial in the United States involving 492 infants.9 10 In almost all the cases in the study the infusion was continued for no more than several hours, the objective being to stabilise the infant in preparation for emergency palliative surgery. PGE1 (rather than PGE2) was chosen for the trial for theoretical reasons, although PGE2 had seemed equally effective. The earlier reports and the collaborative study emphasised the use of infusion of PGE, or PGE2 for a period of a few hours before emergency surgery. Longer term infusion was initially reported in preterm infants, but enthusiasm for its use has probably been limited partly by practical considerations as well as by an appreciable incidence of side effects.6 10 The use of an oral preparation of PGE2 has simplified long term administration." 12 In infants with a ductus dependent pulmonary circulation a single oral dose of PGE2 caused an increase in arterial oxygen content similar to that reported in the US collaborative study when intravenous infusion of PGE1 was used. Arterial oxygen saturation and plasma PGE2 concentration reached similar values whether PGE2 was given orally or by intravenous infusion. These values increased within 15-30 minutes after an oral dose, implying rapid absorption from the alimentary tract. A larger dose caused a proportionately greater increase in plasma PGE2 concentration, confirming that absorption was efficient. Higher plasma PGE2 concentrations, however, were not usually associated with better blood oxygenation, probably because the ductus had been fully dilated by the lower dose. These observations have helped to rationalise both the route of administration and the appropriate dosage.
Hourly administration of oral PGE2 is necessary to maintain arterial oxygenation at satisfactory Pharmacological manipulation of the ductus arteriosus 829 levels for the first week or two. Subsequently, the dosage or its frequency can be reduced. The ductus arteriosus did not remain patent if treatment with PGE2 was stopped, even after many months of treatment, but in some infants it has been possible to lengthen the periods between doses to as much as every 4-6 hours to treat them at home. Long term treatment encouraged growth of the infants and of their pulmonary arteries, which seemed to be advantageous to the surgeons when they performed palliative shunts. 
